Androgens regulate biological pathways to promote proliferation, differentiation, and survival
of benign and malignant prostate tissue. Androgen receptor (AR) targeted therapies exploit …

Prostate cancer (PCa) has become the most common form of cancer in men in the
developed world, and it ranks second in cancer-related deaths. Men that succumb to PCa …

Prostate cancer patient mortality is ascribed to the spread of cancerous cells to areas
outside the prostate gland and the inability of current treatment strategies to effectively block …

Castration resistant prostate cancer (CRPC) remains one of the leading causes of cancer
deaths among men. Conventional therapies targeting androgen signaling driven tumor …

The long-standing challenge in the treatment of prostate cancer is to overcome therapeutic
resistance during progression to lethal disease. Aberrant transforming-growth factor-β (TGF …

Androgen deprivation is currently a standard-of-care, first-line therapy for prostate cancer in
the United States. Although this regimen effectively regresses androgen-dependent disease …

The success of next-generation androgen receptor (AR) pathway inhibitors, such as
abiraterone acetate and enzalutamide, in treating prostate cancer has been hampered by …

The androgen receptor (AR) signaling pathway is critical for growth and differentiation of
prostate cancer cells. For that reason, androgen deprivation therapy with medical or surgical …

Prostate cancer (PCa) is the major cause of cancer-related death among the male
population of Western society, and androgen-deprivation therapy (ADT) represents the first …

Androgen ablation therapy is widely used for the treatment of advanced prostate cancer.
However, the effectiveness of this intervention strategy is generally short-lived as the …